Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.

Onkologie - 1 Apr 2008

Wang Zhen, Wu Yi Long, Zhang Guo Chun, Zhou Qing, Xu Chong Rui, Guo Ai Lin

Abstract excerpt

BACKGROUND: For gefitinib treatment for non-small cell lung cancer (NSCLC), KRAS mutations reportedly behave as a resistance marker, and the epidermal growth factor receptor (EGFR) as a responsive marker. It is known that Asians and Caucasians have different responses to gefitinib. We investigated the KRAS and EGFR mutation status in a group of Chinese patients with advanced NSCLC who were treated with gefitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Proteins

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinazolines

Share to ras Proteins

Source

Identifiers

PMID: 18418018
DOI: 10.1159/000116736

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.PMID 18418018Read ↗

[Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer].Semantic proximity Read ↗

[KRAS and epidermal growth factor receptor gene mutation in non-small cell lung cancer].Semantic proximity Read ↗

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].Semantic proximity Read ↗

Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.Semantic proximity Read ↗

Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.Semantic proximity Read ↗

EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.Semantic proximity Read ↗

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.Semantic proximity Read ↗

[Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer].Semantic proximity Read ↗

Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma.Semantic proximity Read ↗

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.